FDA approves higher-concentration cefovecin for dogs

The FDA has approved a new, higher-concentration cefovecin product for dogs. Convenia RTU for Dogs, approved October 20, 2026, is a ready-to-use 160 mg/mL cefovecin injectable suspension from Zoetis for skin infections in dogs caused by susceptible Staphylococcus pseudintermedius and Streptococcus canis. The label covers secondary superficial pyoderma, abscesses, and wounds, and the product is dispensed by prescription through licensed veterinarians. (fda.gov)

This approval builds on a long-established molecule. FDA first approved Convenia in April 2008 for skin infections in dogs and cats, and the new RTU version uses the same active ingredient, cefovecin sodium, a third-generation cephalosporin. What’s changed is the formulation: Convenia RTU for Dogs is pre-mixed and twice as concentrated as the original product, 160 mg/mL versus 80 mg/mL, while keeping the same labeled dose of 3.6 mg/lb, or 8 mg/kg, given subcutaneously. A second injection may be given if response to therapy isn’t complete. (fda.gov)

The dog-only restriction is one of the most important practical details. FDA said Convenia RTU for Dogs contains benzyl benzoate and propylene glycol, inactive ingredients that may be toxic to cats, so unlike original Convenia, this formulation is not approved for feline use. The product comes in a 10 mL multi-use vial containing 1,600 mg of cefovecin, and FDA says veterinarians should shake the bottle for 60 seconds before each use and administer it with a 20-gauge needle. (fda.gov)

Regulatory records show FDA relied on a bioequivalence pathway rather than requiring new pivotal effectiveness trials. In the FOI summary, Zoetis submitted a masked pharmacokinetic study in 32 Beagle dogs comparing the RTU formulation with marketed Convenia at 8 mg/kg. The geometric mean ratio for AUClast was 0.912 and for Cmax was 0.992, with 90% confidence intervals within FDA’s 0.80 to 1.25 bioequivalence range. A separate injection-site safety study in 16 Beagle dogs found no product-related mortalities, persistent injection-site lesions, or clinically meaningful changes in body weight, food intake, or clinical pathology, although immediate behavioral response at injection was greater in the RTU group and increased with the second injection. (fda.gov)

Zoetis is framing the approval around convenience and adherence. In its announcement, the company said the more concentrated formulation is intended to help more medium and large dogs access single-injection treatment, reducing the day-to-day challenge of oral antibiotic administration at home. That positioning fits the product’s practical advantage: at the same mg/kg dose, the 160 mg/mL suspension requires half the injection volume of the original 80 mg/mL formulation. Zoetis had also flagged a new Convenia formulation as an expected 2026 approval and previously reported Canadian approval for the product earlier in 2026. (fidelity.com)

Why it matters: For veterinary professionals, this approval lands at the intersection of compliance, clinic efficiency, and antimicrobial stewardship. A single in-clinic injection can solve a real adherence problem for some pet parents, especially when oral dosing is unreliable. At the same time, cefovecin remains a third-generation cephalosporin, and published stewardship literature has placed drugs in this class in high-importance categories for human medicine, arguing their use should be scrutinized and guided by likely pathogen susceptibility. In practice, that means the new formulation may improve administration logistics without changing the broader need for case selection, documentation, and careful species-specific handling. (fda.gov)

The other operational issue is inventory clarity. Practices that treat both dogs and cats may now have two cefovecin products with similar branding but different species suitability, and the RTU version’s cat toxicity warning makes storage, staff training, and prescribing safeguards especially important. Because the approval is based on bridging to established Convenia data, clinicians shouldn’t read this as a new spectrum or new indication story; it’s primarily a formulation and handling update with a canine-only label. (fda.gov)

What to watch: Next comes commercialization and real-world adoption. Watch for when Zoetis ships product broadly, whether practices reserve it mainly for larger dogs or adherence-challenged cases, and whether clinics update antimicrobial protocols to distinguish original Convenia from the new dog-only RTU formulation. (fidelity.com)